Financial news in brief: Avecho CBD trial latest; Argent’s milestone delivery; Neurotech reassures ASX by Steve Jones April 29, 2026June 8, 2026 Avecho Biotechnology dosed 244 patients in its phase III insomnia trial, 16% above target, in a […]
‘June will be huge’: Avecho boss bullish ahead of CBD trial analysis by Steve Jones March 26, 2026March 26, 2026
Avecho prepares for potentially ‘transformative’ CBD trial results by Adam Sheldon March 4, 2026June 8, 2026
Financial news in brief: Avecho; InhaleRx; Neurotech; Peak; Zelira; Argent by Adam Sheldon February 2, 2026June 8, 2026
Financial news in brief: Elixinol addresses funding concerns; Aurora growth helped by Australia; Avecho lifts cash, progresses trial; Cann receives NAB extension to finalise settlement; IRX reports lean quarter by Adam Sheldon November 4, 2025February 21, 2026
News in brief: Losses widen for Avecho and Elixinol; InhaleRx secures HREC approval; Zelira cuts deficit; Argent shifts from ‘non-core’ activities by Adam Sheldon August 29, 2025February 21, 2026
News in brief: Shahin becomes Vitura’s largest shareholder; Avecho progresses CBD insomnia trial; Epsilon reports improved cashflow; Zelira locks in R&D loan to advance trial by Adam Sheldon July 31, 2025July 31, 2025
CBD stability boost for Avecho ahead of insomnia clinical trial by Steve Jones June 23, 2023April 30, 2024
